153 related articles for article (PubMed ID: 30724387)
1. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
[TBL] [Abstract][Full Text] [Related]
3. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae.
Maas L; Gao R; Cusumano V; Spartz E; Chowdhury R; Krishna M; Lazarev M; Melia J; Selaru F; Sharma S; Limketkai B; Parian A
Dig Dis Sci; 2023 Oct; 68(10):3994-4000. PubMed ID: 37540392
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies.
Tursi A; Mocci G; Del Gaudio A; Papa A
Expert Opin Biol Ther; 2024 Mar; 24(3):171-189. PubMed ID: 38321868
[TBL] [Abstract][Full Text] [Related]
8. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Hammoudi N; Hassid D; Bonnet J; Tran Minh ML; Baudry C; Vauthier A; Chedouba L; Houzé P; Lourenco N; Aparicio T; Gornet JM; Allez M
Scand J Gastroenterol; 2024 May; 59(5):553-560. PubMed ID: 38353236
[TBL] [Abstract][Full Text] [Related]
9. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
Reinisch W; Gecse K; Halfvarson J; Irving PM; Jahnsen J; Peyrin-Biroulet L; Rogler G; Schreiber S; Danese S
Inflamm Bowel Dis; 2021 Jan; 27(1):106-122. PubMed ID: 32634212
[TBL] [Abstract][Full Text] [Related]
10. Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey.
Sarlós P; Bikar A; Farkas N; Resál T; Szepes Z; Farkas K; Nagy F; Vincze Á; Miheller P; Molnár T
Expert Opin Biol Ther; 2023; 23(8):827-832. PubMed ID: 37161387
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y; Pineton de Chambrun G; Lambert J; Nachury M; Seksik P; Altwegg R; Vuitton L; Stefanescu C; Nancey S; Aubourg A; Serrero M; Filippi J; Desseaux K; Viennot S; Abitbol V; Boualit M; Bourreille A; Giletta C; Buisson A; Roblin X; Dib N; Malamut G; Amiot A; Fumery M; Louis E; Elgharabawy Y; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3365-3378.e5. PubMed ID: 36731588
[TBL] [Abstract][Full Text] [Related]
12. Durability of the First Biologic in Patients with Crohn's Disease: A Nationwide Study from the epi-IIRN.
Atia O; Friss C; Focht G; Magen Rimon R; Ledderman N; Greenfeld S; Ben-Tov A; Loewenberg Weisband Y; Matz E; Gorelik Y; Chowers Y; Dotan I; Turner D
J Crohns Colitis; 2024 Jan; 18(1):38-46. PubMed ID: 37465992
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.
Yu N; Sarwal D; Ash R; Aslinia FM
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645625
[TBL] [Abstract][Full Text] [Related]
14. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.
Kappelman MD; Wohl DA; Herfarth HH; Firestine AM; Adler J; Ammoury RF; Aronow JE; Bass DM; Bass JA; Benkov K; Tobi CB; Boccieri ME; Boyle BM; Brinkman WB; Cabera JM; Chun K; Colletti RB; Dodds CM; Dorsey JM; Ebach DR; Entrena E; Forrest CB; Galanko JA; Grunow JE; Gulati AS; Ivanova A; Jester TW; Kaplan JL; Kugathasan S; Kusek ME; Leibowitz IH; Linville TM; Lipstein EA; Margolis PA; Minar P; Molle-Rios Z; Moses J; Olano KK; Osaba L; Palomo PJ; Pappa H; Park KT; Pashankar DS; Pitch L; Robinson M; Samson CM; Sandberg KC; Schuchard JR; Seid M; Shelly KA; Steiner SJ; Strople JA; Sullivan JS; Tung J; Wali P; Zikry M; Weinberger M; Saeed SA; Bousvaros A
Gastroenterology; 2023 Jul; 165(1):149-161.e7. PubMed ID: 37004887
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.
Szymanska E; Dadalski M; Oracz G; Kierkus J
Prz Gastroenterol; 2015; 10(3):164-8. PubMed ID: 26516383
[TBL] [Abstract][Full Text] [Related]
17. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.
Fay S; Ungar B; Paul S; Levartovsky A; Yavzori M; Fudim E; Picard O; Eliakim R; Ben-Horin S; Roblin X; Kopylov U
Inflamm Bowel Dis; 2017 Nov; 23(11):1924-1929. PubMed ID: 28837524
[TBL] [Abstract][Full Text] [Related]
18. Use of Biologics for the Treatment of Inflammatory Conditions of the Pouch: A Systematic Review.
Godoy-Brewer G; Salem G; Limketkai B; Selaru FM; Grossen A; Policarpo T; Haq Z; Parian AM
J Clin Gastroenterol; 2024 Feb; 58(2):183-194. PubMed ID: 36753457
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn's Disease Initiating Biologics With 3 Years of Follow-Up.
Zhao R; Ding Z; Gupta P; Gozalo L; Bruette R; Johnson VM; Maughn K; Liu Y; Kachroo S
J Health Econ Outcomes Res; 2023; 10(2):111-120. PubMed ID: 38025989
[No Abstract] [Full Text] [Related]
20. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn's Disease: A Multicenter Study.
McCurdy JD; Munir J; Parlow S; Reid J; Yanofsky R; Alenezi T; Meserve J; Becker B; Lahijanian Z; Eddin AH; Mallick R; Ramsay T; Rosenfeld G; Bessissow A; Bessissow T; Jairath V; Singh S; Bruining DH; Macdonald B;
Clin Gastroenterol Hepatol; 2024 May; 22(5):1058-1066.e2. PubMed ID: 38122958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
